The Aspirin Paradox: A Cheap Pill Shows Promise Against Cancer, but Age, Timing, and Funding Stand in the Way

For more than two decades, researchers have observed a pattern in large clinical trials: people who take daily aspirin tend to develop fewer cancers, and those who do develop cancer are less likely to die from it. But the mechanism behind this effect remained unclear, and the risk-benefit calculus — particularly the threat of serious bleeding — kept aspirin from becoming a standard cancer prevention tool.

In March 2025, a study published in Nature by researchers at the University of Cambridge identified a specific molecular pathway through which aspirin suppresses cancer metastasis, offering the first clear mechanistic explanation for what had been an epidemiological observation [1]. The discovery has reignited debate about whether aspirin should be reconsidered as a cancer prevention agent — and for whom.

The New Mechanism: Platelets, Thromboxane, and Immune Suppression

The prevailing hypothesis for aspirin's anti-cancer effect centered on its inhibition of cyclooxygenase-2 (COX-2), an enzyme involved in inflammation and tumor growth [3]. The Cambridge study upended that framework.

The researchers found that aspirin works against cancer metastasis — the process by which cancer cells spread from the original tumor to other organs — by targeting a different pathway entirely. Platelets, the blood cells responsible for clotting, produce a molecule called thromboxane A2 (TXA2). TXA2 activates a protein called ARHGEF1 on T cells, the immune cells that normally attack cancer. This activation suppresses T cell function, allowing circulating tumor cells to evade immune detection and establish metastatic colonies in the lungs, liver, and other organs [1][2].

Low-dose aspirin (75–100 mg daily) inhibits COX-1 in platelets, which reduces TXA2 production. With less TXA2, T cells are released from suppression and can mount an immune response against metastasizing cancer cells. In mouse models, the researchers demonstrated that removing ARHGEF1 specifically from T cells — or reducing TXA2 with aspirin — led to immune-mediated rejection of lung and liver metastases [1].

This is a fundamentally different story from COX-2 inhibition. Rather than acting directly on tumor cells or inflammation, aspirin appears to restore the immune system's ability to detect and destroy cancer cells during the vulnerable window when they enter the bloodstream [2].

Which Cancers, and How Much Protection?

The strength of evidence varies substantially by cancer type. Meta-analyses of randomized controlled trials and large cohort studies have produced the following relative risk reductions with long-term aspirin use:

Source: Meta-analyses of RCTs (Rothwell et al., Lancet; CAPP2; Hong Kong Cohort)

Data as of Jan 1, 2025CSV

Gastrointestinal cancers — colorectal, esophageal, gastric, liver, and pancreatic — show the largest and most consistent reductions [5][9]. This aligns with the newly described TXA2 pathway, since the gut is heavily vascularized and metastasis through the portal circulation to the liver is a primary mode of cancer spread in these organs.

For breast and prostate cancers, observational studies have shown reductions in metastasis rates among aspirin users, and these cancers are included in the ongoing Add-Aspirin trial [7]. However, the evidence base is thinner and relies more heavily on observational data rather than randomized trials with cancer as a primary endpoint.

For lung cancer, the relative risk reduction is modest (~10%) and has not been consistently replicated across study designs [5]. The mechanistic link to the TXA2 pathway for lung primary tumors — as opposed to metastases to the lung — remains speculative.

Absolute Risk Reduction: The Numbers That Matter

Relative risk reductions can overstate clinical significance. In absolute terms, the 10-year cumulative colorectal cancer incidence was 1.98% among regular aspirin users compared to 2.95% among non-users — an absolute risk reduction of 0.97 percentage points [4]. For individuals with the unhealthiest lifestyle profiles, the absolute reduction was larger (1.28 percentage points), while for the healthiest individuals it was just 0.11 percentage points [4].

The picture changes dramatically in high-risk genetic populations. In the CAPP2 trial of Lynch syndrome carriers — people with inherited DNA mismatch repair defects who face a lifetime colorectal cancer risk of 50–80% — participants who took 600 mg aspirin daily for at least two years saw a 59% reduction in colorectal cancer incidence [6]. Among all randomized participants in CAPP2, 9% of aspirin recipients developed colorectal cancer compared to 13% of placebo recipients [6].

The Bleeding Problem: Risk Rises Sharply with Age

Aspirin's anti-cancer potential cannot be evaluated in isolation from its primary known harm: increased bleeding. Low-dose aspirin raises the risk of gastrointestinal hemorrhage, intracranial bleeding, and hemorrhagic stroke. The risk escalates steeply with age [10][11].

Source: USPSTF Systematic Review; ASPREE Trial

Data as of Jan 1, 2024CSV

The overall incidence of major GI bleeding with low-dose aspirin is approximately 1.4 events per 1,000 person-years in men and 1.7 per 1,000 person-years in women [10]. But baseline bleeding risk roughly doubles with each decade after age 50, and additional risk factors — hypertension, diabetes, concurrent use of other NSAIDs or anticoagulants, history of peptic ulcer — compound the danger [10][11].

In the ASPREE trial, which enrolled 19,114 healthy adults aged 70 and older, daily 100 mg aspirin showed no reduction in cancer incidence over a median 8.6-year follow-up. Among participants who did develop cancer, those on aspirin had a 15% higher risk of cancer-related death [8]. The investigators found no evidence of a delayed protective "legacy effect" even years after stopping aspirin [8].

This finding is central to the current regulatory posture. The U.S. Preventive Services Task Force (USPSTF), in its 2022 recommendation, gave a "D" rating — recommending against — initiating aspirin for primary cardiovascular prevention in adults 60 and older, and suggested stopping aspirin at approximately age 75 for those already taking it [11]. For adults 40–59 with elevated cardiovascular risk, the USPSTF assigned a "C" rating, indicating a small net benefit that should be weighed individually [11].

How Long Before Protection Emerges?

One of the most consistent findings across studies is that aspirin's cancer-protective effect takes years to appear. In the CAPP2 Lynch syndrome trial, there was no difference between aspirin and placebo groups at the end of the intervention period (average 2.5 years), but a significant protective effect emerged at 4.6 years of follow-up [6]. In cardiovascular trial reanalyses, the benefit for cancer mortality did not become apparent until at least 5 years, with the absolute reduction in 20-year cancer death risk reaching 7.08 percentage points at age 65 [5].

A 2025 Hong Kong cohort study of 1.5 million residents found that use of aspirin for six or more years was associated with a 19% decreased risk of colorectal cancer and a 15% decreased risk of any gastrointestinal cancer. Stronger effects were observed with more than 10 years of use, including reductions in lung, breast, and colorectal cancers [9].

Whether stopping aspirin eliminates the benefit is less clear. The CAPP2 data suggest the protective effect persists well beyond the treatment period — participants took aspirin for an average of 2.5 years, and the cancer reduction was measurable at 10 and 20 years of follow-up [6]. But the ASPREE trial, which studied older adults, found no legacy effect [8]. This discrepancy may reflect differences in the populations studied — younger Lynch syndrome carriers versus healthy septuagenarians — or in the biology of cancer initiation versus metastasis.

The Skeptical Case

Not all researchers are convinced that aspirin's apparent cancer benefits are real, or at least as large as reported.

Several methodological concerns persist. Many of the strongest results come from reanalyses of cardiovascular prevention trials where cancer was not the primary endpoint. This introduces the possibility of post-hoc bias in endpoint selection [12][13]. The Women's Health Study and the Physicians' Health Study — two large randomized trials — did not show a cancer benefit with alternate-day aspirin, and their lower susceptibility to bias as RCTs with cancer as a pre-specified endpoint should be weighed against positive findings from other analyses [12].

Observational studies face the problem of healthy-user bias: people who take daily aspirin may also be more health-conscious, more likely to undergo screening, and more likely to have regular medical care. While some studies have attempted to control for these confounders, residual confounding from unmeasured variables — family history, diet, physical activity — cannot be excluded [12][13].

Publication bias is another concern. Meta-analyses that aggregate published literature may overestimate aspirin's effect because studies with null or negative results are less likely to be published [12].

The ASPREE trial result — no benefit and possible harm in older adults — provides the strongest counterpoint from a randomized design. Critics argue that if aspirin truly prevented cancer through a robust biological mechanism, some signal should have been detectable in a trial of nearly 20,000 people followed for nearly a decade [8].

Defenders of the aspirin-cancer hypothesis counter that ASPREE enrolled only older adults who had already passed through the age window where aspirin's protective effect appears strongest, and that the TXA2-immune pathway described in the Cambridge study specifically addresses metastasis prevention, not primary tumor formation [1][2].

Equity and Access

Lynch syndrome affects roughly 1 in 279 people and is the most common hereditary cancer predisposition syndrome [6]. For these individuals, the evidence for aspirin's benefit is strongest and most actionable. But Lynch syndrome is underdiagnosed, particularly in communities with limited access to genetic testing — which includes much of the developing world and underserved populations in wealthy countries.

Aspirin itself is among the cheapest and most widely available drugs on earth. A year's supply of low-dose aspirin costs under $15 in most countries and is available without prescription. This makes it an attractive candidate for global cancer prevention, particularly in settings where expensive screening and treatment options are unavailable.

However, the populations most likely to benefit from aspirin for cancer prevention — younger adults with elevated cancer risk or genetic predispositions — do not entirely overlap with those advised against aspirin due to bleeding risk. The USPSTF's recommendation against aspirin in adults over 60 primarily targets cardiovascular prevention, not cancer. A formal cancer-prevention indication, with age-stratified guidelines, could shift the net benefit calculation for specific groups.

The Funding Gap

Aspirin went off patent in 1930. No pharmaceutical company stands to profit from proving it prevents cancer. This creates a structural gap in the clinical trial pipeline [7].

The largest ongoing trial, Add-Aspirin, completed recruitment in 2025 after a decade of effort. It enrolled over 10,000 people with breast, colorectal, prostate, or gastro-oesophageal cancer to test whether aspirin reduces recurrence. The trial is funded entirely by public and charitable sources: Cancer Research UK, the UK National Institute for Health Research, and the Medical Research Council [7].

The SPARC consortium (Stratified Prevention and Risk Communication), led by University College London and funded by Cancer Research UK, is working to understand how aspirin can best be used for cancer prevention [7]. The ASCOLT trial, which ran from 2009 to 2021 across 66 hospitals in 11 countries, was similarly funded by academic and public health institutions [14].

Source: OpenAlex

Data as of Jan 1, 2026CSV

Research output on aspirin and cancer prevention has grown substantially, peaking at over 5,400 papers published in 2023 [15]. But this academic interest has not translated into industry-sponsored phase III trials of the kind that typically drive guideline changes. Without proprietary incentive, the path from mechanistic discovery to revised clinical recommendations depends entirely on government and nonprofit funding — a process that is slower and less well-resourced than industry-driven drug development.

Where This Leaves Patients and Clinicians

The evidence now available presents a paradox. The biological mechanism linking aspirin to cancer protection is more clearly defined than ever. The TXA2-ARHGEF1 pathway offers a concrete, testable target and explains decades of epidemiological observations [1]. For specific populations — Lynch syndrome carriers, younger adults with elevated colorectal cancer risk, patients with PI3K-mutated tumors — the data are strong enough that some clinical guidelines already recommend aspirin [6][14].

But for the general population, particularly adults over 60, the risk-benefit balance remains unfavorable. The ASPREE data suggest that starting aspirin late in life does not reduce cancer risk and may increase cancer mortality [8]. The USPSTF's 2022 pullback from cardiovascular aspirin recommendations applies added caution [11].

The critical unanswered question is whether starting aspirin earlier — in the 40s or 50s, when the bleeding risk is lower and the latency period aligns with the decade-long lag before cancer protection emerges — would produce net clinical benefit for average-risk individuals. Answering that question definitively will require large, long-duration randomized trials with cancer as the primary endpoint. Given aspirin's off-patent status and the absence of industry funding, those trials will depend on public investment in a drug that costs pennies a day.